Supported by in-house scientists and a first-in-class Macrophage Therapeutics Development Platform, Creative Biolabs is confident in providing an integrated solution for the development of macrophage-targeted liposome drug delivery systems to facilitate your project success.
As important players, macrophages are associated with many important activities and can be polarized following activation into classic (or M1) and alternative (or M2) macrophages. With the further exploration of the role of macrophages in several diseases including infectious disease, inflammatory diseases, cancer, and atherosclerosis, strategies to target macrophages have become increasingly important in both scientific and therapeutic research.
As particulate carriers, liposomes are the most widely investigated delivery system providing advantages such as low immunogenicity, biocompatibility, cell specificity and drug protection. Targeting of liposomes to macrophages can be achieved by modifying lipid composition to control physicochemical properties such as size and charge and by the inclusion of surface ligands including proteins, peptides, antibodies, polysaccharides, glycolipids, glycoproteins, and lectins. Macrophage-targeted liposome drug delivery systems promise to be an efficient means in the field of diseases.
Scientists at Creative Biolabs are dedicated to bringing together years of valuable experience to help our clients shorten the clinical study journey. We are committed to providing an integrated solution for the development of macrophage-targeted liposome drug delivery systems to reduce the overall project development timeline for our clients.
For further details, please don't hesitate to contact us and see how we can help you reach your project requirements.